Evidence map›Paper›PMID 36942103›Full record

ArticleComputational and structural biotechnology journal2023

Splicing signature database development to delineate cancer pathways using literature mining and transcriptome machine learning.

Kyubin Lee, Daejin Hyung, Soo Young Cho, Namhee Yu, Sewha Hong, Jihyun Kim, Sunshin Kim, Ji-Youn Han, Charny Park

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kyubin LeeResearch Institute, National Cancer Center, 232 Ilsan-ro, Goyang-si, Gyeonggi-do 10408, Republic of Korea.
Daejin HyungResearch Institute, National Cancer Center, 232 Ilsan-ro, Goyang-si, Gyeonggi-do 10408, Republic of Korea.
Soo Young ChoDepartment of Molecular & Life Science, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan-si, Gyeonggi-do 15588, Republic of Korea.
Namhee YuResearch Institute, National Cancer Center, 232 Ilsan-ro, Goyang-si, Gyeonggi-do 10408, Republic of Korea.
Sewha HongResearch Institute, National Cancer Center, 232 Ilsan-ro, Goyang-si, Gyeonggi-do 10408, Republic of Korea.
Jihyun KimResearch Institute, National Cancer Center, 232 Ilsan-ro, Goyang-si, Gyeonggi-do 10408, Republic of Korea.
Sunshin KimResearch Institute, National Cancer Center, 232 Ilsan-ro, Goyang-si, Gyeonggi-do 10408, Republic of Korea.
Ji-Youn HanResearch Institute, National Cancer Center, 232 Ilsan-ro, Goyang-si, Gyeonggi-do 10408, Republic of Korea.
Charny ParkResearch Institute, National Cancer Center, 232 Ilsan-ro, Goyang-si, Gyeonggi-do 10408, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alternative splicing (AS) events modulate certain pathways and phenotypic plasticity in cancer. Although previous studies have computationally analyzed splicing events, it is still a challenge to uncover biological functions induced by reliable AS events from tremendous candidates. To provide essential splicing event signatures to assess pathway regulation, we developed a database by collecting two datasets: (i) reported literature and (ii) cancer transcriptome profile. The former includes knowledge-based splicing signatures collected from 63,229 PubMed abstracts using natural language processing, extracted for 202 pathways. The latter is the machine learning-based splicing signatures identified from pan-cancer transcriptome for 16 cancer types and 42 pathways. We established six different learning models to classify pathway activities from splicing profiles as a learning dataset. Top-ranked AS events by learning model feature importance became the signature for each pathway. To validate our learning results, we performed evaluations by (i) performance metrics, (ii) differential AS sets acquired from external datasets, and (iii) our knowledge-based signatures. The area under the receiver operating characteristic values of the learning models did not exhibit any drastic difference. However, random-forest distinctly presented the best performance to compare with the AS sets identified from external datasets and our knowledge-based signatures. Therefore, we used the signatures obtained from the random-forest model. Our database provided the clinical characteristics of the AS signatures, including survival test, molecular subtype, and tumor microenvironment. The regulation by splicing factors was additionally investigated. Our database for developed signatures supported retrieval and visualization system.

Indexed as

Alternative splicingAS, Alternative splicingAUCPR, the area under the precision-recall curveAUROC, the area under the receiver operating characteristicDAS, differential alternative splicingDatabaseEMT, epithelial mesenchymal transitionGene signatureMachine-learningML, machine learningNER, named entity recognitionNLP, natural language processPCA, principal component analysisPSI, percent spliced in indexRF, random-forestSF, splicing factorTCGA, The Cancer Genome AtlasText-miningTumor transcriptome

Identifiers

PMID36942103
PMCPMC10023904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.